Cilostazol Reduces the Risk of Hemorrhagic Infarction After Administration of Tissue-Type Plasminogen Activator in a Murine Stroke Model
- 1 February 2012
- journal article
- research article
- Published by Wolters Kluwer Health in Stroke
- Vol. 43 (2) , 499-506
Abstract
Background and Purpose—: Prior use of antiplatelet agents improves stroke outcome in patients undergoing thrombolytic therapy as shown by reduced arterial reocclusion, although the risk of cerebral hemorrhage can be increased. Methods—: The effect of cilostazol, an antiplatelet drug that improves endothelial function through upregulation of intracellular cAMP, on cerebral hemorrhage after thrombolytic therapy was investigated using a highly reproducible transient ischemia model. Results—: Treatment with cilostazol for 7 days before ischemia significantly suppressed the risk and severity of cerebral hemorrhage after injection of tissue-type plasminogen activator, although treatment with aspirin had no such protective effect compared with nontreated mice. Immunohistological analysis revealed that treatment with cilostazol suppressed disruption of the microvasculature in the ischemic area associated with reduced matrix metalloproteinase-9 activity. Conclusions—: Our results suggest that patients treated with cilostazol before onset of stroke could have a lower risk of cerebral hemorrhage after thrombolytic therapy and might also have a longer therapeutic time window for thrombolysis. Furthermore, the risk of cerebral hemorrhage can be significantly altered by prestroke therapies, and analysis of the effects of multiple drugs on tissue-type plasminogen activator-induced cerebral hemorrhage in animal models is essential for the extending safe and effective thrombolytic therapy to a wider group of patients.Keywords
This publication has 52 references indexed in Scilit:
- Role of matrix metalloproteinase‐9 (MMP‐9) in striatal blood–brain barrier disruption in a 3‐nitropropionic acid model of Huntington's diseaseNeuropathology and Applied Neurobiology, 2011
- PECAM-1 regulates proangiogenic properties of endothelial cells through modulation of cell-cell and cell-matrix interactionsAmerican Journal of Physiology-Cell Physiology, 2010
- Reduced Ischemic Brain Injury by Partial Rejuvenation of Bone Marrow Cells in Aged RatsJournal of Cerebral Blood Flow & Metabolism, 2010
- A randomised controlled trial of antiplatelet therapy in combination with Rt-PA thrombolysis in ischemic stroke: rationale and design of the ARTIS-TrialTrials, 2010
- Matrix Metalloproteinase-9 Mediates Hypoxia-Induced Vascular Leakage in the Brain via Tight Junction RearrangementJournal of Cerebral Blood Flow & Metabolism, 2009
- Cilostazol, a Phosphodiesterase Inhibitor, Attenuates Photothrombotic Focal Ischemic Brain Injury in Hypertensive RatsJournal of Cerebral Blood Flow & Metabolism, 2009
- The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor simvastatin reduces thrombolytic-induced intracerebral hemorrhage in embolized rabbitsBrain Research, 2009
- Cilostazol Protects Endothelial Cells Against Lipopolysaccharide-Induced Apoptosis Through ERK1/2- and P38 MAPK-Dependent PathwaysThe Korean Journal of Internal Medicine, 2009
- Spontaneous intracerebral haemorrhage in adults: a literature overviewActa Neurochirurgica, 2008
- Mechanisms of the Anti-Ischemic Effect of Angiotensin II AT1 Receptor Antagonists in the BrainCellular and Molecular Neurobiology, 2006